BioLine RX Ltd APHEXDA Investor Conference Call Transcript
Good morning, and welcome to the BioLineRx APHEXDA FDA approval conference call. My name is [Yoni Schottenstein], and I will be your operator for today's call. (Operator Instructions)
It is my pleasure to introduce John Lacey, Head of Investor Relations and Corporate Communications at BioLine Rx. John, you may begin the call.
Thank you, Yoni. Welcome, everyone, to this morning's call, where we are very pleased to discuss the U.S. Food and Drug Administration's approval of APHEXDA, the trade name for motixafortide.
Joining me today are Phil Serlin, our Chief Executive Officer; Holly May, President of BioLineRx USA; and Beth Giblin, US Head of Medical Affairs. In addition, Ella Sorani, our Chief Development Officer, will be joining the call for Q&A.
I'd like to remind you that certain statements we make during the call will be forward looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
